Printer Friendly

BIO-VASCULAR WILL BEGIN CLINICAL TRIALS OF SMALL DIAMETER GRAFT

 BIO-VASCULAR WILL BEGIN CLINICAL TRIALS OF SMALL DIAMETER GRAFT
 ST. PAUL, MINN., March 17 /PRNewswire/ -- Bio-Vascular, Inc. (NASDAQ: BVAS) today reported that the U.S. Food and Drug Administration has approved its application for an investigational device exemption (IDE) that would allow the company to begin human clinical trials of its Bioflow(R) Small Diameter Graft in coronary artery bypass cases.
 John Darnall, president and chief executive officer of Bio-Vascular, said the clinical work is expected to begin soon.
 The Bioflow Small Diameter Graft is a biosynthetic blood conduit using bovine arteries that have been treated with special chemical agents to eliminate rejection, strengthen the graft and sterilize the tissue. The graft has been used in more than 1,000 procedures overseas, principally in Western Europe, Japan and Australia, of which more than half involved use of the graft in coronary artery bypass operations.
 "We are pleased to have cleared this initial hurdle with the FDA and look forward to the beginning of clinical work aimed at qualifying the graft in the United States," Darnall said. He said that the initial IDE allows a total of 15 implants at two clinical sites, but that the scope of the investigation may be expanded based on the outcome of the initial cases.
 The Bioflow Small Diameter Graft is also being evaluated as a systemic-pulmonary shunt under a separate IDE. That study is continuing, Darnall said.
 Bio-Vascular, Inc., based in St. Paul, is a manufacturer and marketer of proprietary consumable medical products for cardiac and vascular surgery.
 -0- 3/17/92
 /CONTACT: Curt Swenson of Swenson Falker Eilertsen, 612-371-0000, for Bio-Vascular, or John H. Darnall Jr. or M. Karen Gilles, both of Bio-Vascular, 612-631-3529/
 (BVAS) CO: Bio-Vascular, Inc. ST: Minnesota IN: MTC SU:


AL -- MN008 -- 8822 03/17/92 14:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 17, 1992
Words:299
Previous Article:MCI AWARDED FAA 'LINCS' CONTRACT TO LINK NATION'S AIR CONTROL SYSTEM
Next Article:CONNECTICUT LIGHT & POWER SENIOR DEBT RAISED TO 'A-' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
BIO-VASCULAR REPORTS GAINS IN THIRD QUARTER SALES, NET INCOME
POSSIS RECEIVES IDE APPROVAL FROM FDA
BIO-VASCULAR NAMES SCHANKERELI DIRECTOR OF RESEARCH AND DEVELOPMENT
BIO-VASCULAR DISCONTINUES CLINICAL TRIALS OF BIOFLOW GRAFT
BIO-VASCULAR NAMES KEMAL SHANKERELI VICE PRESIDENT OF RESEARCH AND DEVELOPMENT
POSSIS MEDICAL ANNOUNCES FIRST CORONARY ANGIOJET THROMBECTOMY
CARDIOTECH INTERNATIONAL, INC. TO PRESENT AT THE CRUTTENDEN ROTH HEALTHCARE GROWTH STOCK CONFERENCE
CLINICAL DATA SUPPORTS ENDOVASCULAR TECHNOLOGIES' EGS(R) SYSTEM
CARDIOTECH INT'L, INC. INITIATES EUROPEAN CLINICAL TRIALS ON VASCULAR ACCESS GRAFTS
Possis Medical, Inc. Seeks FDA Approval to Begin Stroke Clinical Trial with the AngioJet System

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters